Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069125
Filing Date
2025-05-12
Accepted
2025-05-12 16:00:22
Documents
69
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cue-20250331.htm   iXBRL 10-Q 1364444
2 EX-3.1 cue-ex3_1.htm EX-3.1 93311
3 BI COLLABORATION cue-ex10_2.htm EX-10.2 797565
4 EINSTEIN AMENDMENT cue-ex10_3.htm EX-10.3 89127
5 EX-31.1 cue-ex31_1.htm EX-31.1 14225
6 EX-31.2 cue-ex31_2.htm EX-31.2 14293
7 EX-32.1 cue-ex32_1.htm EX-32.1 12582
8 GRAPHIC img78868092_0.jpg GRAPHIC 40040
  Complete submission text file 0000950170-25-069125.txt   7928619

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cue-20250331.xsd EX-101.SCH 1290262
71 EXTRACTED XBRL INSTANCE DOCUMENT cue-20250331_htm.xml XML 936065
Mailing Address 40 GUEST STREET BOSTON MA 02135
Business Address 40 GUEST STREET BOSTON MA 02135 617-949-2680
Cue Biopharma, Inc. (Filer) CIK: 0001645460 (see all company filings)

EIN.: 473324577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38327 | Film No.: 25934565
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)